The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer

被引：0
|
作者：
Yang Zhang
Yuanyuan Zeng
Ting Liu
Wenwen Du
Jianjie Zhu
Zeyi Liu
Jian-an Huang
机构：
[1] the First Affiliated Hospital of Soochow University,Department of Respiratory Medicine
[2] Suzhou Key Laboratory for Respiratory Diseases,undefined
[3] Institute of Respiratory Diseases,undefined
[4] Soochow University,undefined
来源：
Respiratory Research | / 20卷
关键词：
PD-L1; EGFR-TKI; Drug resistance; TGF-β/Smad signalling; NSCLC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer
    Zhang, Yang
    Zeng, Yuanyuan
    Liu, Ting
    Du, Wenwen
    Zhu, Jianjie
    Liu, Zeyi
    Huang, Jian-an
    RESPIRATORY RESEARCH, 2019, 20
  • [2] Genomic characteristics of PD-L1-Induced resistance to EGFR-TKIs in lung adenocarcinoma
    Yi, Guangming
    Cai, Fanghao
    Liu, Liangzhong
    Liao, Rongxin
    Jiang, Xuan
    Yang, Zhenzhou
    Zhang, Xiaoyue
    FUTURE ONCOLOGY, 2024, 20 (40) : 3477 - 3490
  • [3] Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer
    Lei, Si-Yu
    Xu, Hai-Yan
    Li, Hong-Shuai
    Yang, Ya-Ning
    Xu, Fei
    Li, Jun-Ling
    Wang, Zhi-Jie
    Xing, Pu-Yuan
    Hao, Xue-Zhi
    Wang, Yan
    THORACIC CANCER, 2023, 14 (24) : 2327 - 2337
  • [4] miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance
    Ricciuti, Biagio
    Mecca, Carmen
    Cenci, Matteo
    Leonardi, Giulia Costanza
    Perrone, Lorenzo
    Mencaroni, Clelia
    Crino, Lucio
    Grignani, Francesco
    Baglivo, Sara
    Chiari, Rita
    Sidoni, Angelo
    Paglialunga, Luca
    Curra, Maria Francesca
    Murano, Emanuele
    Minotti, Vincenzo
    Metro, Giulio
    ECANCERMEDICALSCIENCE, 2015, 9
  • [5] AFATINIB IN EGFR MUTANT NON-SMALL-CELL LUNG CANCER PATIENTS WITH ACQUIRED RESISTANCE TO REVERSIBLE EGFR-TKIS
    Cappuzzo, Federico
    Tiseo, Marcello
    Chiari, Rita
    Landi, Lorenza
    Ricciardi, Serena
    Rossi, Elisa
    Galetta, Domenico
    Novello, Silvia
    Milella, Michele
    D'Incecco, Armida
    Haspinger, Eva Regina
    Cortinovis, Diego
    Santo, Antonio
    Banna, Giuseppe
    Facchi-Netti, Francesco
    Levra, Matteo Giaj
    Vari, Sabrina
    Crino, Lucio
    De Marinis, Filippo
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S610 - S610
  • [6] Small-cell lung cancer transformation from EGFR-mutant adenocarcinoma after EGFR-TKIs resistance A case report
    Jiang, Yiqian
    Shou, Leyi
    Guo, Qingmin
    Bao, Yanhong
    Xu, Xiaoping
    An, Suhong
    Lu, Jianfeng
    MEDICINE, 2021, 100 (32) : E26911
  • [7] The role of PD-L1 in EGFR-mutant non-small cell lung cancer
    Gao, Wentao
    Wang, Lingling
    Zhao, Yanyan
    Zhu, Lucheng
    DISCOVER ONCOLOGY, 2025, 16 (01)
  • [8] EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance
    Fogli, Stefano
    Polini, Beatrice
    Del Re, Marzia
    Petrini, Iacopo
    Passaro, Antonio
    Crucitta, Stefania
    Rofi, Eleonora
    Danesi, Romano
    PHARMACOGENOMICS, 2018, 19 (08) : 727 - 740
  • [9] Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer
    Cai, Xueting
    Miao, Jing
    Sun, Rongwei
    Wang, Sainan
    Molina-Vila, Miguel Angel
    Chaib, Imane
    Rosell, Rafael
    Cao, Peng
    PHARMACOLOGICAL RESEARCH, 2021, 170
  • [10] Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer
    Han, Jae Joon
    Kim, Dong-Wan
    Koh, Jaemoon
    Keam, Bhumsuk
    Kim, Tae Min
    Jeon, Yoon Kyung
    Lee, Se-Hoon
    Chung, Doo Hyun
    Heo, Dae Seog
    CLINICAL LUNG CANCER, 2016, 17 (04) : 263 - +
12345